Devonian Advances Thykamine(TM) Patent Strategy with Proprietary Fingerprint and Robust Manufacturing Controls
MWN-AI** Summary
Devonian Health Group Inc. has recently announced significant advancements in its patent strategy regarding its innovative product, Thykamine™. Central to this progress is the formal filing of a proprietary “Thykamine™ fingerprint” in two new patent applications, which will become a key element of the company’s long-term intellectual property approach. This fingerprint identifies eight specific chemical components in precise ratios, determined by advanced High-Performance Liquid Chromatography-Mass Spectrometry (HPLC-MS) methods.
The HPLC-MS methodology reveals high reproducibility across produced batches of Thykamine™, confirmed by Nuclear Magnetic Resonance (NMR) analysis indicating a consistency rate of over 98%. This level of batch reproducibility has been further validated through potency assays using a human cell-based model, establishing that each batch maintains equivalent biological activity, particularly in the inhibition of inflammatory cytokines. The company is working to integrate these findings into the Chemistry, Manufacturing, and Controls (CMC) framework for Thykamine™.
Dr. André Boulet, Devonian's CEO, emphasized the importance of these methods in demonstrating the chemical consistency and biological efficacy of Thykamine™. The proprietary fingerprinting technique and robust manufacturing controls assure the regulatory preparedness necessary for developing pharmaceutical-grade products.
Thykamine™, developed from Devonian’s SUPREX™ platform, addresses health conditions linked to inflammation and oxidative stress. Conditions include ulcerative colitis, atopic dermatitis, and rheumatoid arthritis. The product's therapeutic potential has been supported by various studies, including Phase II clinical trials. With ongoing patent protection across multiple countries, Devonian is committed to advancing Thykamine™ while ensuring high quality and efficacy in its offerings.
MWN-AI** Analysis
Devonian Health Group Inc. has made significant strides in strengthening its Thykamine™ patent strategy by integrating a proprietary chemical fingerprint and robust manufacturing controls. This move is strategically vital as it not only forms the backbone of their intellectual property but also enhances the reliability and quality of Thykamine™ as a pharmaceutical product. With its capacity to address inflammatory and oxidative stress-related conditions, Thykamine™ stands out in a competitive market that craves innovative and effective therapeutic options.
The rigorous HPLC-MS analytical method, validated by NMR confirmation and potency assays, showcases Devonian’s commitment to ensuring consistent product quality across batches. Such high reproducibility will likely appease regulatory bodies while providing healthcare professionals and patients with confidence in product reliability. Given the growing emphasis on drug efficacy and safety, the emphasis on extensive quality control may differentiate Thykamine™ from less-regulated competitors.
Furthermore, the strategic filing of patents in various global jurisdictions strengthens Devonian's market position, potentially creating high barriers for new entrants. As autoimmune diseases, such as ulcerative colitis and rheumatoid arthritis, become increasingly prevalent, the demand for solutions like Thykamine™ is anticipated to rise. Investors should monitor the company's progression through clinical trials and regulatory approvals, as successful outcomes could significantly enhance market penetration and profitability.
In light of these developments, potential investors should view Devonian's advancements as a promising sign of growth. However, as with any clinical-stage biopharmaceutical, intrinsic risks remain. Continuous development updates and clinical data releases will be crucial indicators to watch. As the landscape evolves, positioning with Devonian could yield a rewarding opportunity—albeit accompanied by inherent volatility typical of the biotech sector.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
Canada NewsWire
QUEBEC, Feb. 17, 2026 /CNW/ - Devonian Health Group Inc. ("Devonian" or the Company) (TSXV: GSD) (OTCQB: DVHGF) today announced that a proprietary Thykamine™ fingerprint has been formally filed in two recent patent applications and is now a core component of the Company's long-term intellectual property and patent strategy. This fingerprint will be systematically incorporated into all future Thykamine™-related patent filings.
The Thykamine™ fingerprint defines eight specific chemical components present in precise ratios, established using advanced HPLC-MS (High-Performance Liquid Chromatography–Mass Spectrometry) analytical methods. The HPLC-MS methodology has demonstrated high reproducibility across manufactured batches of Thykamine™, a result independently confirmed by NMR (Nuclear Magnetic Resonance) analysis, showing ?98% confidence in batch-to-batch consistency.
Batch reproducibility was further validated through potency assays using a U-937 human cell-based model, demonstrating that every batch of Thykamine™ exhibits equivalent biological activity. These assays confirmed consistent inhibition of key inflammatory cytokines, including RANTES and MIP-1?, reinforcing the functional equivalence of each production batch. The potency assay is currently being validated for inclusion in the Chemistry, Manufacturing and Controls (CMC) section of Thykamine™ production.
Collectively, the HPLC-MS fingerprinting, NMR confirmation, and potency assays will form an integral part of Devonian's CMC framework for Thykamine™ production, reinforcing regulatory preparedness and ensuring the level of manufacturing robustness required for pharmaceutical development.
Dr. André Boulet, Chief Executive Officer of Devonian, commented: "These analytical and biological methods clearly demonstrate the quality and consistency of Thykamine™ produced in every batch--not only from a chemical standpoint, but also as an active anti-inflammatory and anti-fibrotic pharmaceutical. This integrated approach provides strong confidence that patients will consistently receive a product of the same high quality, efficacy, and reliability."
This milestone reinforces Devonian's commitment to scientific rigor, intellectual property protection, and pharmaceutical-grade manufacturing as the Company continues to advance Thykamine™ through development.
About Thykamine™
Thykamine™, the first pharmaceutical product issued from Devonian's SUPREX™ platform, is a highly innovative product for the prevention and treatment of health conditions related to inflammation and oxidative stress including ulcerative colitis, atopic dermatitis, psoriasis, rheumatoid arthritis, and other autoimmune disorders. The anti-inflammatory, anti-oxidative and immunomodulatory properties of Thykamine™ have been demonstrated by a considerable number of in vitro and in vivo studies as well as in a Phase IIa clinical study in patients with mild-to-moderate distal ulcerative colitis and in a large Phase II study in adult patients with mild-to-moderate Atopic Dermatitis. Both Thykamine™ and SUPREX™ platform are covered by patents issued in several North American, European and Asian countries.
About Devonian
Devonian Health Group Inc. is a clinical stage pharmaceutical company specializing in the development of drugs for various auto-immune fibroinflammatory disease with novel therapeutic approaches to targeting unmet medical needs. Devonian's core strategy is to develop prescription drugs for the treatment of fibroinflammatory autoimmune diseases including but not limited to atopic dermatitis, radiodermatitis and ulcerative colitis.
Devonian is also involved in the development of high-value cosmeceutical products leveraging the same proprietary approach employed with their pharmaceutical offerings. Devonian also owns a commercialization subsidiary, Altius Healthcare LP, focused on selling prescription pharmaceutical products in Canada, under licenses from brand name pharmaceutical companies.
Devonian Health Group Inc. was incorporated in 2015 and is headquartered in Quebec, Canada where it owns a state-of-the art extraction facility. Devonian is traded publicly on the TSX Venture Exchange (the "Exchange") (TSXV: GSD) and currently quoted on the OTCQB Venture Market (OTCQB: DVHGF).
For more information, visit www.groupedevonian.com.
Cautionary Note Regarding Forward-Looking Statements
All statements, other than statements of historical fact, contained in this press release including, but not limited to those relating to the Common Shares consolidation; the anticipated post-consolidation trading price of the Common Shares; the potential impact of the consolidation on investor interest and liquidity; the ability to satisfy minimum price or other listing requirements of U.S and other stock exchanges; the impacts in perceived trading price following the consolidation; the ability of the Company to maintain compliance with regulatory requirements following the consolidation; and generally, the above "About Devonian" paragraph, all of which essentially describes the Company's outlook, constitute "forward-looking information" or "forward-looking statements" within the meaning of certain securities laws (collectively, "forward-looking statements"), and are based on expectations, estimates and projections as of the time of this press release. Such forward-looking statements may be identified by the use of words such as "intends", "believes", "expects", or variations (including negative and grammatical variations) of such words and phrases, or state that certain actions, events or results "may", "could", "would", or "will" be taken, occur or be achieved.
Forward-looking statements are necessarily based upon a number of estimates and assumptions that, while considered reasonable by the Company as of the time of such statements, are inherently subject to significant business, economic and competitive uncertainties and contingencies. These estimates and assumptions may prove to be incorrect. Many of these uncertainties and contingencies can directly or indirectly affect, and could cause, actual results to differ materially from those expressed or implied in any forward-looking statements. There can be no assurance that these assumptions will prove to be correct and there can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements.
By their very nature, forward-looking statements involve inherent risks and uncertainties, both general and specific, and risks exist that estimates, forecasts, projections and other forward-looking statements will not be achieved or that assumptions do not reflect future experience. Forward-looking statements are provided for the purpose of providing information about management's expectations and plans relating to the future. Readers are cautioned not to place undue reliance on these forward-looking statements as a number of important risk factors and future events could cause the actual outcomes to differ materially from the beliefs, plans, objectives, expectations, anticipations, estimates, assumptions and intentions expressed in such forward-looking statements. All of the forward-looking statements made in this press release are qualified by these cautionary statements and those made in our other filings with the applicable securities regulators of Canada. The Company disclaims any intention or obligation to update or revise any forward-looking statements or to explain any material difference between subsequent actual events and such forward-looking statements, except to the extent required by applicable law.
Neither the Exchange nor its Regulation Services Provider (as that term is defined in policies of the Exchange) accepts responsibility for the adequacy or accuracy of this release.
SOURCE Devonian Health Group Inc.
View original content to download multimedia: http://www.newswire.ca/en/releases/archive/February2026/17/c7697.html
FAQ**
How does the Thykamine™ fingerprint improve Devonian Health Group Inc. (DVHGF)'s competitive advantage in the pharmaceutical market, particularly against other anti-inflammatory products?
What specific regulatory hurdles does Devonian Health Group Inc. (DVHGF) anticipate in the future development of Thykamine™, and how does the newly established CMC framework address these challenges?
Can you elaborate on the role of HPLC-MS and potency assays in ensuring the consistency and efficacy of Thykamine™, and how this enhances investor confidence in Devonian Health Group Inc. (DVHGF)?
What measures is Devonian Health Group Inc. (DVHGF) taking to protect its intellectual property related to Thykamine™, and how might potential patent protections impact the company's long-term growth strategy?
**MWN-AI FAQ is based on asking OpenAI questions about Devonian Health Group Inc. (TSXVC: GSD:CC).
NASDAQ: GSD:CC
GSD:CC Trading
3.13% G/L:
$0.66 Last:
61,720 Volume:
$0.56 Open:
